Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC)
A Randomized, Placebo-controlled Phase II b(OEV 123) Study to Evaluate Safety, Immunogenicity, Diagnostic Methodology, and Estimate Vaccine Efficacy of an Oral Enterotoxigenic Escherichia Coli(ETEC) Vaccine(ETVAX) for Prevention of Clinically Significant ETEC Diarrhea in Healthy Adult Travelers Visiting West Africa
Sponsor: Göteborg University
This PHASE2 trial investigates Diarrhea and is currently completed. Göteborg University leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Dec 2019 — Apr 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 2 earlier versions
-
Apr 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2018 — Apr 2019 [monthly]
Recruiting PHASE2
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Göteborg University
- Oy Medfiles Ltd
- Scandinavian Biopharma AB
- United Medix Laboratories Ltd.
- University of Helsinki
- University of Virginia
For direct contact, visit the study record on ClinicalTrials.gov .